ATS to gain $13 million from shares sale:
This article was originally published in Clinica
ATS Medical is to sell approximately 3.7 million shares of common stock at $3.55 per share to certain institutional investors. The sale is expected to earn Minneapolis, Minnesota-based ATS $13.1m. The developer of heart valves and cardiovascular instruments plans to use the proceeds for general working capital purposes and to finance the manufacturing of its ATS open pivot valve, which, according to the company, has been implanted in over 85,000 patients. Some of the funds will also be used for the introduction of the PARSUS blood filtration technology for which ATS recently acquired worldwide rights from Swedish firm ErySave (see Clinica No 1106, p 24).
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.